Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Did DEA have any part in Purdues decision to “temporarily suspend” distribution of the 160 mg. strength tablet?

April 26, 2017DEA decision distribution MG purdues strength tablet temporarily suspend

0

10 Posted

Did DEA have any part in Purdues decision to “temporarily suspend” distribution of the 160 mg. strength tablet?

1 Answer

0

10 Posted

DEA has expressed its concerns to Purdue regarding the diversion and abuse of their OxyContin products. DEA recognizes the therapeutic value of long-acting opioids in the treatment of chronic pain. However, it has been found that the controlled release formulation used in OxyContin products can be easily compromised. The ability to quickly release a high dose of oxycodone that is intended for slow release, whether intentional or not, makes this product both attractive to abusers and dangerous to individuals who have not developed a tolerance to opioids. DEA has not asked Purdue to withdraw the 160 mg. tablet and recognizes that this dosage may be appropriate for a limited number of patients. The Associate Press reported on May 11, 2001, that Purdue stated that government pressure played no part in its decision to suspend distribution of OxyContin 160 mg. tablets. It would not be appropriate for DEA to speculate about the decision.